In this study HCV negative recipients will be transplanted with HCV positive lungs.
Investigators will attempt to decrease infectivity rates by performing Normothermic Ex vivo
Lung Perfusion (EVLP), which is an approved method of donor lung preservation, assessment and
treatment, and could be an excellent platform to reduce/eliminate hepatitis C virus. Patients
will be treated by the standard approved direct-acting antivirals (DAAs) if infection occurs.
It is planned to enrolled 20 patients from the Lung transplant wait list in this study.
Patients will be followed for 6 months. This will be a single center pilot study.
Phase:
Early Phase 1
Details
Lead Sponsor:
Marcelo Cypel University Health Network, Toronto
Collaborators:
Gilead Sciences University Health Network, Toronto
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir